IntegraGen Acquires Exclusive License to Metastatic Colon Cancer Biomarker | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm IntegraGen said today that it has acquired the exclusive rights to use a specific microRNA as a biomarker for predicting patient outcomes in metastatic colorectal cancer.

The license was obtained from the Paris Descartes University, INSERM, the Centre National de la Recherche Scientifique, and the Assistance Publique — Hopitaux de Paris. Terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.